Does TYK2/JAK1 Show Potential in Inflammatory Diseases? - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.

  • By

  • Andrea Surnit

  • July 6, 2026

  • 3 min

Share

  • 1

    SDC-1801 was well tolerated in a phase 1 trial with 95 healthy participants, showing no mortality or serious adverse events.

  • 2

    The study observed pharmacologic activity, with reductions in IP-10 and high-sensitivity C-reactive protein in multiple-dose cohorts.

  • 3

    Pharmacokinetic analyses indicated peak plasma concentrations occurred 3 to 5 hours post-administration, with a half-life of 15 to 27 hours.

  • 4

    Food intake modestly increased drug exposure, suggesting improved absorption through enhanced solubilization.

  • 5

    The study's limitations include its focus on healthy participants and formulation-related differences affecting dose proportionality.

Original Source(s)

Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

  • by Andrea Surnit

  • July 6, 2026

Related Content

Emergency diagnosis may flag poor outcomes beyond cancer

Across 13 noncancer conditions, emergency diagnosis was common and associated with higher 1-year mortality.

In Vivo CAR T: A New Route to Treating Autoimmune Disease

How targeted in vivo CAR T delivery could pave the way for autoimmune disease treatments

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial